Figure 3
From: Rosiglitazone blocks first trimester in-vitro placental injury caused by NF-κB-mediated inflammation
Rosiglitazone reversed LPS mediated reduction in trophoblast differentiation marker expression. Expression of trophoblast differentiation markers GCM1 and CG-β was assessed at mRNA level by qPCR (A,B) and protein level using western blotting and ELISA (C,D). LPS exposure downregulated expression of both mRNA and protein levels of GCM1 and CG-β which were induced by Rosiglitazone treatment. n = 4–8, ‘*’ indicates significance at p < 0.05 when compared to the PBS control group, ‘#’ indicates significance at p < 0.05 when compared to the LPS treated group.
